Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • marinolman11 marinolman11 Aug 22, 2014 9:05 AM Flag

    twitter post

    Not sure if its a retread
    Citation: The PLOS ONE Staff (2014) Correction: Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling. PLoS ONE 9(8): e106797. doi:10.1371/journal.pone.0106797

    Published: August 21, 2014

    Copyright: © 201

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$
      This correction simply updates the participant and funding disclosures.
      Here's the straight skinny from PlosOne:
      There are some missing funding sources for this article. Please refer to the correct funding statement below:
      "The studies in this manuscript were funded by Exelixis Inc.; PO1 National Institutes of Health grant (PO1CA085859); Pacific Northwest Prostate Cancer SPORE grant (P50CA097186); Prostate Cancer Foundation; Richard M. Lucas Foundation; and University of Washington Bridge funding. Two of the co-authors (DTA and FS) are employees of Exelixis. They were involved in study design, data analyses, decision to publish and preparation of the manuscript"

 
EXEL
3.44-0.05(-1.43%)Jul 2 4:00 PMEDT